1
|
Kuttke M, Gugenberger R, Thell K, Bischof S, Peball B, Muehleisen H, Urban M, Gapp B, Bugajska-Schretter A, Halfmann A, Morley P, Dohnal A. 15P Enhancement Platform for immune Cells (EPiC): invIOs’s innovative cell-therapy platform for creating personalized cancer treatments. ESMO Open 2023. [DOI: 10.1016/j.esmoop.2023.100981] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/11/2023] Open
|
2
|
Thell K, Urban M, Harrauer J, Haslinger I, Kuttke M, Brunner J, Vogel A, Schabbauer G, Penninger J, Gaweco A. Master checkpoint Cbl-b inhibition: Anti-tumour efficacy in a murine colorectal cancer model following siRNA-based cell therapy. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz253.057] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
4
|
Kuttke M, Sahin E, Pisoni J, Percig S, Vogel A, Kraemmer D, Hanzl L, Brunner JS, Paar H, Soukup K, Halfmann A, Dohnal AM, Steiner CW, Blüml S, Basilio J, Hochreiter B, Salzmann M, Hoesel B, Lametschwandtner G, Eferl R, Schmid JA, Schabbauer G. Myeloid PTEN deficiency impairs tumor-immune surveillance via immune-checkpoint inhibition. Oncoimmunology 2016; 5:e1164918. [PMID: 27622019 PMCID: PMC5006931 DOI: 10.1080/2162402x.2016.1164918] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2015] [Revised: 03/03/2016] [Accepted: 03/08/2016] [Indexed: 12/14/2022] Open
Abstract
Tumor-host interaction is determined by constant immune surveillance, characterized by tumor infiltration of myeloid and lymphoid cells. A malfunctioning or diverted immune response promotes tumor growth and metastasis. Recent advances had been made, by treating of certain tumor types, such as melanoma, with T-cell checkpoint inhibitors. This highlights the importance of understanding the molecular mechanisms underlying the crosstalk between tumors and their environment, in particular myeloid and lymphoid cells. Our aim was to study the contribution of the myeloid PI3K/PTEN-signaling pathway in the regulation of tumor-immune surveillance in murine models of cancer. We made use of conditional PTEN-deficient mice, which exhibit sustained activation of the PI3K-signaling axis in a variety of myeloid cell subsets such as macrophages and dendritic cells (DCs). In colitis-associated colon cancer (CAC), mice deficient in myeloid PTEN showed a markedly higher tumor burden and decreased survival. We attributed this observation to the increased presence of immune-modulatory conventional CD8α(+) DCs in the spleen, whereas other relevant myeloid cell subsets were largely unaffected. Notably, we detected enhanced surface expression of PD-L1 and PD-L2 on these DCs. As a consequence, tumoricidal T-cell responses were hampered or redirected. Taken together, our findings indicated an unanticipated role for the PI3K/PTEN-signaling axis in the functional regulation of splenic antigen-presenting cells (APCs). Our data pointed at potential, indirect, tumoricidal effects of subclass-specific PI3K inhibitors, which are currently under clinical investigation for treatment of tumors, via myeloid cell activation.
Collapse
Affiliation(s)
- M Kuttke
- Institute for Physiology, Center for Physiology and Pharmacology, Medical University of Vienna Vienna, Austria
| | - E Sahin
- Institute for Physiology, Center for Physiology and Pharmacology, Medical University of Vienna Vienna, Austria
| | - J Pisoni
- Institute for Physiology, Center for Physiology and Pharmacology, Medical University of Vienna Vienna, Austria
| | - S Percig
- Institute for Physiology, Center for Physiology and Pharmacology, Medical University of Vienna Vienna, Austria
| | - A Vogel
- Institute for Physiology, Center for Physiology and Pharmacology, Medical University of Vienna Vienna, Austria
| | - D Kraemmer
- Institute for Physiology, Center for Physiology and Pharmacology, Medical University of Vienna Vienna, Austria
| | - L Hanzl
- Institute for Physiology, Center for Physiology and Pharmacology, Medical University of Vienna Vienna, Austria
| | - J S Brunner
- Institute for Physiology, Center for Physiology and Pharmacology, Medical University of Vienna Vienna, Austria
| | - H Paar
- Institute for Physiology, Center for Physiology and Pharmacology, Medical University of Vienna Vienna, Austria
| | - K Soukup
- St. Anna Children's Cancer Research Institute , Vienna, Austria
| | - A Halfmann
- St. Anna Children's Cancer Research Institute , Vienna, Austria
| | - A M Dohnal
- St. Anna Children's Cancer Research Institute , Vienna, Austria
| | - C W Steiner
- Department of Rheumatology Internal Medicine III, Medical University of Vienna , Vienna, Austria
| | - S Blüml
- Department of Rheumatology Internal Medicine III, Medical University of Vienna , Vienna, Austria
| | - J Basilio
- Institute for Vascular Biology and Thrombosis Research, Center for Physiology and Pharmacology Medical University of Vienna , Vienna, Austria
| | - B Hochreiter
- Institute for Vascular Biology and Thrombosis Research, Center for Physiology and Pharmacology Medical University of Vienna , Vienna, Austria
| | - M Salzmann
- Institute for Vascular Biology and Thrombosis Research, Center for Physiology and Pharmacology Medical University of Vienna , Vienna, Austria
| | - B Hoesel
- Institute for Vascular Biology and Thrombosis Research, Center for Physiology and Pharmacology Medical University of Vienna , Vienna, Austria
| | | | - R Eferl
- Institute of Cancer Research, Internal Medicine I, Medical University of Vienna , Vienna, Austria
| | - J A Schmid
- Institute for Vascular Biology and Thrombosis Research, Center for Physiology and Pharmacology Medical University of Vienna , Vienna, Austria
| | - G Schabbauer
- Institute for Physiology, Center for Physiology and Pharmacology, Medical University of Vienna Vienna, Austria
| |
Collapse
|